

TAKAFULINK DANA EKUITI GLOBAL

All information as at 31 August 2023 unless otherwise stated


Semua maklumat adalah seperti pada 31 Ogos 2023 melainkan jika dinyatakan

Objective / Objektif Dana

Takafulink Dana Ekuiti Global aims to provide capital appreciation by investing in Shariah-compliant investments with exposure to the global equity markets.

Takafulink Dana Ekuiti Global bertujuan untuk menyediakan peningkatan nilai modal dengan melabur dalam sekuriti patuh Syariah melalui pendedahan terhadap pasaran ekuiti global.

Where the Fund invests Komposisi Pelaburan Dana



Asset Allocation Peruntukan Aset


	% NAV
1 abrdn Islamic World Equity Fund	99.53
2 Cash, Deposits & Others	0.47

Fund Details / Maklumat Terperinci Dana

Investment Manager / Pengurus Pelaburan	Prudential BSN Takaful Berhad
Inception Date / Tarikh Diterbitkan	08/07/2019
Current Fund Size / Saiz Dana Terkini	RM22,531,667.06
Annual Fund Management Charge / Caj Pengurusan Dana Tahunan	1.5% p.a.
Current NAV / NAB Terkini	RM1.44364

How the Fund has performed / Prestasi Dana

Performance Graph / Jaduan Prestasi Dana
Takafulink Dana Ekuiti Global Vs. MSCI ACWI Islamic (Shariah) Index



Total Price Movement Over the Following Periods / Jumlah Pergerakan Harga Dalam Tempoh Tersebut

	1 month	3 months	6 months	1 year	3 years	5 years	Since Inception
Price Movement / Pergerakan Harga	0.86%	5.27%	12.77%	18.40%	24.54%	NA	44.36%
Benchmark / Penanda Aras	0.27%	7.24%	15.80%	22.85%	46.91%	NA	61.01%
Outperformance / Perbezaan Prestasi	0.59%	-1.97%	-3.03%	-4.45%	-22.37%	NA	-16.65%

TAKAFULINK DANA EKUITI GLOBAL

All information as at 31 August 2023 unless otherwise stated

Semua maklumat adalah seperti pada 31 Ogos 2023 melainkan jika dinyatakan

Monthly Update / Laporan Bulanan Terkini

Fund Review & Strategy

Global Markets declined over the month as a resilient US economy and still-high inflation stoked fears of further monetary tightening. However, it was a month of two halves. Initially, investors grew concerned that central banks could announce further interest-rate hikes as US economic data remained solid and officials reiterated their concerns about inflation. Fears over China's economy and overindebted property sector did little to improve sentiment. However, softer-than-expected PMI data in the US helped alleviate concerns and supported markets in the second half of August. Looking at individual stock contributions, DSM Firmenich reported weak second quarter organic sales and provided a similarly weak outlook. However, higher contract prices and improved cost discipline should lead to a margin recovery in 2024. The legacy Firmenich business also continued to perform resiliently. Resmed's shares sold off after its fourth quarter results. Gross margin pressure, poor management communication, the threat of re-entry from a key competitor and GLP-1 medications all provided headwinds. ASML was also among the main laggards. Semiconductor shares sold off over August given concerns that AI demand may be cooling off. China's weak industrial/ consumer demand and constrained cloud capital expenditure in the US also provided headwinds. More positively, Goodman reported results ahead of its upgraded guidance driven by strong operational performance. Demand is expected to remain strong. Novo Nordisk performed well on the back of positive trial results for its obesity drug, Wegovy. This significantly increases the probability of widespread commercial use. Altium's shares spiked higher after better-than-expected results as demand continued for design software and build-printed circuit boards. Portfolio activity was muted over the month.

Tinjauan dan Strategi Dana

Pasaran Global merosot pada bulan dagangan berikutan ekonomi US yang mampan di samping inflasi yang masih tinggi mencetuskan kebimbangan pengetatan monetari selanjutnya. Walau bagaimanapun, keadaan ini terbahagi dua bahagian dalam sebulan. Pada separuh pertama, pelabur semakin bimbang bahawa bank pusat boleh mengumumkan kenaikan kadar faedah selanjutnya memandangkan data ekonomi US yang mantap dan pegawai mengulangi kebimbangan tentang inflasi. Kegusaran terhadap ekonomi China dan sektor hartanah yang terlalu banyak berhutang tidak banyak membantu merangsang sentimen. Walau bagaimanapun, data PMI di US yang lebih lembut daripada jangkaan membantu mengurangkan kebimbangan dan menyokong pasaran pada separuh kedua bulan Ogos. Meninjau sumbangan saham individu, DSM Firmenich melaporkan jualan organik suku kedua yang lemah lalu memberikan prospek yang juga lemah. Namun begitu, harga kontrak yang lebih tinggi dan disiplin kos yang lebih baik sewajarnya akan membawa kepada pemulihan margin pada tahun 2024. Legasi perniagaan Firmenich juga terus menunjukkan prestasi yang mampan. Saham Resmed terjual selepas keputusan suku keempatnya. Tekanan margin kasar, komunikasi pengurusan yang lemah, ancaman kemasukan semula pesaing utama dan ubat-ubatan GLP-1 semuanya menjadi kekangan. ASML juga antara yang paling jauh ketinggalan. Saham semikonduktor terjual pada Ogos memandangkan kebimbangan bahawa permintaan terhadap AI mungkin berkurangan. Permintaan perindustrian/ pengguna China yang lemah dan perbelanjaan modal awan yang terhad di US juga menimbulkan masalah. Meninjau sudut lebih positif, Goodman melaporkan hasil mendahului panduan yang dinaik taraf, didorong oleh prestasi operasi yang kukuh. Permintaan dijangka kekal kukuh. Novo Nordisk menunjukkan prestasi yang baik berdasarkan keputusan percubaan ubat obesitinya yang positif, Wegovy. Ia dengan ketara meningkatkan kebarangkalian penggunaan komersial yang meluas. Saham Altium melonjak lebih tinggi selepas keputusan yang lebih baik daripada jangkaan apabila permintaan berterusan ke atas reka bentuk perisian dan binaan papan litar bercetak. Aktiviti portfolio mendarat di sepanjang bulan.

Source / Sumber: Fund Commentary, August 2023, N/A

Disclaimer

Investments are subject to investment risks including the possible loss of the principal amount invested. The value of the units may fall as well as rise. Past performances of the funds and that of the fund managers are not necessarily indicative of future performance. The price movements indicated are not reflective of the actual return on your investments (which are subject to your premium allocation rate and deduction charges). The actual return on your invested premiums may fluctuate based on the underlying performance of the investment-linked funds. All Takafulink Dana are invested in Shariah-approved securities and/or Islamic private debt securities. This leaflet is for illustrative purposes only. For further details on the terms and conditions, please refer to the policy document. For further details on how you can invest in these funds, please refer to the respective product brochures. In the event of discrepancy between the information in this fact sheet and the policy document, the information in the policy document shall prevail.

Pelaburan adalah tertakluk kepada risiko-risiko pelaburan termasuk kemungkinan kehilangan jumlah wang pokok yang dilabur. Nilai unit mungkin naik ataupun jatuh. Prestasi masa dulu dana-dana atau pengurus-pengurus dana tidak semestinya mencerminkan prestasi masa depan. Pergerakan harga yang ditunjukkan tidak menggambarkan pulangan sebenar pelaburan anda (yang tertakluk kepada kadar peruntukan premium dan caj potongan). Pulangan sebenar ke atas premium yang anda labur mungkin berbeza, bergantung kepada prestasi dana-dana). Semua Takafulink Dana dilaburkan dalam sekuriti yang diluluskan oleh Syariah dan/atau sekuriti hutang swasta Islam. Risalah ini disediakan hanya untuk gambaran semata-mata. Sila rujuk kepada dokumen polisi untuk keterangan lanjut mengenai terma-terma dan syarat-syarat. Untuk keterangan lanjut mengenai bagaimana anda boleh melabur dalam dana-dana ini, sila rujuk kepada risalah-risalah produk yang berkenaan. Jika terdapat perbezaan di antara helaian fakta dan dokumen polisi, maklumat dalam dokumen polisi dianggap muktamad.

PRUDENTIAL BSN

TAKAFUL